Brazilian Grape Tree Extract.

Jaboticaba peel is rich in ellagitannins, which gut bacteria hydrolyse to ellagic acid and then convert to urolithins. The berry extract is a precursor to the same metabolite the isolate delivers directly.

The ellagitannins in jaboticaba release ellagic acid on hydrolysis in the gut. Pairing them raises exposure to one molecule from a bound and a free form.

Ascorbate reduces the phenoxyl radicals formed when anthocyanins and other flavonoids take an oxidative hit, returning them to their active form. The two sit next to each other in the same redox chain.

Tocopherol handles chain-breaking in membranes while the anthocyanins of jaboticaba act in the aqueous phase and help regenerate the tocopheroxyl radical. The two phases are covered by one pairing.

Jaboticaba carries quercetin derivatives alongside its anthocyanins, and both are handled by the same phase II conjugation enzymes. Combining them raises the load on that shared clearance route.

Both supply oligomeric proanthocyanidins that act on endothelial nitric oxide signalling and collagen cross-linking. The pairing is additive rather than mechanistically distinct.

Tannins and anthocyanin-rich polyphenols bind non-heme iron in the gut lumen and lower its uptake. Taken in the same sitting the berry extract works against an iron supplement.

Ferrous salts are the classic non-heme form most affected by tannin binding, which forms poorly absorbed complexes in the gut. Separating the two by a couple of hours is standard practice.

Whether jaboticaba ellagitannins become urolithins depends on which gut bacteria are present, since only some species carry out the conversion. Microbial composition sets how much of the extract becomes an active metabolite.

Resveratrol and jaboticaba polyphenols are cleared by the same sulfotransferase and glucuronosyltransferase enzymes. Co-dosing raises competition at that shared step, which changes circulating levels of both.

Jaboticaba peel and bilberry both carry anthocyanins, with cyanidin-3-O-glucoside and delphinidin glycosides prominent. The two therefore reach the same conjugating enzymes and the same colonic microbial degradation route once swallowed. Combining them raises total anthocyanin intake without adding a new mechanism, and both are absorbed poorly in their intact glycoside form.

Most anthocyanins and ellagitannins are not absorbed intact; the colonic microbiota cleaves them into smaller phenolic acids and, in the case of ellagitannins, into urolithins. Which metabolites appear depends heavily on which organisms are present, and people differ markedly in that capacity. A probiotic does not guarantee conversion, but the conversion step is genuinely microbial and not enzymatic in the human gut.

Bifidobacteria contribute glycosidase activity that releases the aglycone from anthocyanin glycosides in the colon. The released phenolic fragments are what actually reach circulation in most cases. This is an established property of the community rather than a demonstrated effect of any single strain with this extract.

Fermentable fibre feeds the colonic bacteria that perform polyphenol catabolism and lowers luminal pH, which alters anthocyanin stability. The pairing is common in formulation for that reason. It is a plausible mechanistic combination, not one resting on a trial of these two together.

Phospholipid complexes and liposomal dispersions are a standard formulation answer to poorly absorbed polyphenols, improving dispersion at the intestinal surface. The approach is well documented for polyphenols generally. Whether it changes anything for this particular extract has not been established, so the claim stays at the formulation level.

Polyphenols with catechol and galloyl groups bind divalent cations in the intestinal lumen, forming complexes that neither partner absorbs well. Calcium taken at the same time as a concentrated polyphenol dose is subject to this. Separating the two by a couple of hours is the standard way around it.

Zinc, like iron and calcium, is chelated by dietary polyphenols in the gut lumen, which lowers the fraction available for uptake. The effect is dose dependent and applies to concentrated extracts more than to whole fruit. Timing separates them.

Polyphenols bind readily to proline-rich and other dietary proteins, which is the chemistry behind astringency and behind the loss of measurable free polyphenol when berry extracts are mixed into a protein drink. The bound fraction is not necessarily lost, since digestion can release some of it, but the free polyphenol available at the gut surface falls. Formulators either accept this or keep the two apart.

Casein binds anthocyanins and tannins strongly, which is why milk is the classic way to blunt the astringency of a polyphenol-rich drink. Adding a casein-based product to a berry extract reduces the free polyphenol measurable in the mixture. Whether that changes what reaches the colon is less clear.

Dietary polyphenols are conjugated by the same UGT and SULT enzymes and pumped back into the lumen by the same efflux transporters. Large simultaneous doses of two polyphenol extracts compete for that limited conjugating capacity, which can raise the free fraction of one or both. The direction of the net effect is not predictable from the mechanism alone.

Reviews of Brazilian and Amazonian fruit composition describe carotenoids alongside the phenolic fraction, and carotenoids act in the lipid phase while anthocyanins act in the aqueous phase. Pairing the two covers different compartments. The grounding here is compositional analysis of fruit, not a supplementation study.

Carotenoids need a fat vehicle for absorption, while anthocyanins do not, so the two travel by different routes from the same meal. In a formulation the phenolic fraction can slow oxidative loss of the carotenoid during storage. This is chemistry in the bottle plus a compositional observation, and no clinical combination data supports it.